Trinity Biotech

Historical price data

Trinity Biotech is a publicly-traded diagnostics company on a mission to provide high-quality clinical testing solutions globally. Recent key achievements include regaining compliance with NASDAQ listing requirements, securing the prestigious IFCC Gold Classification for 2026 for its Premier Hb9210™ HbA1c analyzer, and obtaining regulatory approval to commence offshored manufacturing for its flagship Uni-Gold™ HIV test. The company's core strategy revolves around transforming its financial performance through cost-structure optimization via manufacturing offshoring and outsourcing, while leveraging its established portfolio in hemoglobinopathies, infectious disease, and autoimmune diagnostics.

Multi-platform diagnostics company utilizing lateral flow immunoassays for point-of-care testing, High-Performance Liquid Chromatography (HPLC) for hemoglobin and diabetes analysis, clinical chemistry reagents for automated analyzers, and specialized reference laboratory services.

Trinity Biotech competes with global IVD giants (e.g., Abbott, Roche, Siemens) in clinical chemistry and diabetes, and with specialized players in hemoglobin analysis (Bio-Rad, Tosoh) and rapid HIV testing. Its small scale and financial limitations are significant disadvantages, though niche expertise and recent product recognition offer points of differentiation.